Cargando…
Trial by CCN2: a standardized test for fibroproliferative disease?
A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relativ...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686749/ https://www.ncbi.nlm.nih.gov/pubmed/19266315 http://dx.doi.org/10.1007/s12079-009-0041-y |
| _version_ | 1782167471653912576 |
|---|---|
| author | Leask, Andrew |
| author_facet | Leask, Andrew |
| author_sort | Leask, Andrew |
| collection | PubMed |
| description | A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relative levels of vascular endothelial growth factor (VEGF) and CCN2 (connective tissue growth factor [CTGF]) were examined in proliferative diabetic retinopathy (PDR). This paper is the subject of this commentary. |
| format | Text |
| id | pubmed-2686749 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2009 |
| publisher | Springer Netherlands |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-26867492009-06-08 Trial by CCN2: a standardized test for fibroproliferative disease? Leask, Andrew J Cell Commun Signal Bits and Bytes A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relative levels of vascular endothelial growth factor (VEGF) and CCN2 (connective tissue growth factor [CTGF]) were examined in proliferative diabetic retinopathy (PDR). This paper is the subject of this commentary. Springer Netherlands 2009-03-07 2009-03 /pmc/articles/PMC2686749/ /pubmed/19266315 http://dx.doi.org/10.1007/s12079-009-0041-y Text en © The Author(s) 2009 |
| spellingShingle | Bits and Bytes Leask, Andrew Trial by CCN2: a standardized test for fibroproliferative disease? |
| title | Trial by CCN2: a standardized test for fibroproliferative disease? |
| title_full | Trial by CCN2: a standardized test for fibroproliferative disease? |
| title_fullStr | Trial by CCN2: a standardized test for fibroproliferative disease? |
| title_full_unstemmed | Trial by CCN2: a standardized test for fibroproliferative disease? |
| title_short | Trial by CCN2: a standardized test for fibroproliferative disease? |
| title_sort | trial by ccn2: a standardized test for fibroproliferative disease? |
| topic | Bits and Bytes |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686749/ https://www.ncbi.nlm.nih.gov/pubmed/19266315 http://dx.doi.org/10.1007/s12079-009-0041-y |
| work_keys_str_mv | AT leaskandrew trialbyccn2astandardizedtestforfibroproliferativedisease |